IAS HIV Cure & Cancer Forum
22 & 23 July 2017
Institut Curie, Paris, France

SATURDAY 22 JULY 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8h00 – 9h00</td>
<td>Registration</td>
</tr>
<tr>
<td>9h00 – 10h00</td>
<td>Opening Session&lt;br&gt;Welcome and Introduction&lt;br&gt;Françoise Barré-Sinoussi, France&lt;br&gt;Jack Whitescarver, United States</td>
</tr>
<tr>
<td></td>
<td>Keynote&lt;br&gt;HIV/AIDS and Cancer cure: Is it the same battle?&lt;br&gt;Monsef Benkirane, Institute of Human Genetics, CNRS, France</td>
</tr>
<tr>
<td>10h00 – 11h10</td>
<td>Session 1&lt;br&gt;Burden of Disease&lt;br&gt;Diana Finzi, Division of AIDS, NIAID, NIH, United States&lt;br&gt;Nicolas Chomont, Université de Montréal, CRCHUM, Canada</td>
</tr>
<tr>
<td></td>
<td>Invited speakers&lt;br&gt;Real time detection of viral replication kinetics: A tool to identify functional viral reservoirs&lt;br&gt;François Villinger, New Iberia Research Center, University of Lousianna at Lafayette, United States</td>
</tr>
<tr>
<td></td>
<td>Liquid Biopsies: Monitoring the Cancer Genome in Blood&lt;br&gt;Sarah-Jane Dawson, Peter MacCallum Cancer Centre, Australia</td>
</tr>
<tr>
<td></td>
<td>OA1-1&lt;br&gt;Impact of vorinostat treatment of non-Hodgkin’s lymphoma on HIV-1 latent reservoir&lt;br&gt;Adam Capoferrri, Johns Hopkins University School of Medicine, United States</td>
</tr>
<tr>
<td></td>
<td>OA1-2&lt;br&gt;Enrichment of the HIV reservoir in CD32+ CD4 T cells occurs early and is closely associated with immune checkpoint receptor expression&lt;br&gt;Genevieve Martin, University of Oxford, United Kingdom</td>
</tr>
<tr>
<td>11h10 – 11h40</td>
<td>Break</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| **11h40 – 13h00** | **Session 2** | **Epigenetic Control of HIV-1 Latency: From Molecular Targets to Cure Strategies** | Olivier Rohr, University of Strasbourg/ IUT Louis Pasteur, France  
Rafick-Pierre Sekaly, Case Western Reserve University, United States  
Geneviève Almouzni, Institut Curie, France  
Jonathan Karn, Case Western Reserve University, United States  
Carine Van Lint, Université Libre de Bruxelles (ULB), Belgium  
Christina Gavegnano, Emory University, United States  
Isa Munoz-Arias, University of California, San Francisco, United States |
| **OA2-1**  | Invited Speakers | **Chromatin dynamics – epigenetic parameters and cellular fate**  
**Epigenetic control of HIV latency** | Jonathan Karn, Case Western Reserve University, United States  
Identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1  
JAK inhibitors employ novel mechanisms to block reservoir seeding and HIV persistence  
Small-Molecule Chemotherapeutic Drugs Reactivate HIV-1 via Non-Canonical Pathways and Modulate CD8 T cell response |
| **OA2-2**  | **OA2-3** | **General Discussion 10’** |                                                                                                                                         |
| **OA2-3**  | **OA3-1** | **Immunology and Immunotherapy** | Daniel Douek, VRC, NIAIDS, United States  
Laurence Weiss, Hôpital Européen Georges Pompidou, France  
Aurélien Marabelle, Gustave Roussy, France  
Sebastian Amigorena, Institut Curie, France  
Brigitte Autran, APHP - Hôpital Pitié Salpêtrière, France |
| **13h00 – 14h00** | **Lunch** |                                                                                                                                 |                                                                                                                                         |
| **14h00 – 15h20** | **Session 3** | **Paradigm shift in cancer therapy: targeting immune cells rather than cancer cells**  
**Epigenetic control of T cell memory differentiation** | Aurélien Marabelle, Gustave Roussy, France  
Sebastian Amigorena, Institut Curie, France  
HIV reservoir dynamics and immune responses after anti-PD-1 therapy  
PD-1 blockade in 12 HIV-infected patients with lung cancer |
### OA3-3

**Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T-cells**  
*Sharon Lewin, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Australia*

**General Discussion 10’**

### 15h20 – 16h30  
**Session 4**  
**Immune Modulation and HIV Infection**

José Alcami, Instituto de Salud, Spain  
Nina Russell, Bill & Melinda Gates Foundation, United States

**Invited Speakers**

**Tissue Inflammation profiles: lessons for HIV/SIV control**  
Michaëla Muller-Trutwin, Institut Pasteur, France

*Interferon epsilon regulation of mucosal immune response in infection and cancer*  
Paul Hertzog, Hudson Institute of Medical Research, Australia

**OA4-1**

Combined IL-21 and IFNα treatment limits residual inflammation, viral persistence and delays viral rebound in SIV-infected Rhesus macaques  
*Mirko Paiardini, Yerkes National Primate Research Center, Emory University, United States*

**OA4-2**

Evaluation of Different Treg Depletion Approaches as Strategies for Improved SIV Reactivation and Clearance  
*Ranjit Sivanandham, Center for Vaccine Research, University of Pittsburgh, United States*

**General Discussion 10’**

### 16h30 – 18h00  
**Poster Exhibition & Networking Session**

---

**SUNDAY 23 JULY 2017**

### 9h00 – 10h00  
**Session 5**  
**Gene Therapy**

Keith Jerome, Fred Hutchinson Cancer Research Center, United States  
Monique Nijhuis, University Medical Center Utrecht, Netherlands

**Invited Speakers**

**Fast generation of the T cell compartment by using a ligand of Notch: Possible application to HIV affected patients**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>10h00</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
| 10h30  | **Session 6**  
**Clinical Trial Design and Participation**                               | Sharon Lewin, The Doherty Institute, University of Melbourne, Australia  |
|        |                                                                                 | Olivier Lambotte, APHP – Hôpital Bicêtre, France                         |
|        |                                                                                 | Jinatanat Ananworanich, US Military HIV Research Program, United States  |
|        |                                                                                 | Michael Louella, University of Washington AIDS Clinical Trials Unit, United States |
|        |                                                                                 | Jean-Philippe Spano, Pitié-Salpêtrière University Hospital, France        |
|        |                                                                                 | Gilliosa Spurrier, Mélanome France, France                               |
|        |                                                                                 | Thomas Uldrick, Center for Cancer Research, NCI, United States           |
| 12h00  | Closing Session  
**Closing Lecture**  
**Antibodies for Tumor Immunotherapy (and HIV?)** | Steven Deeks, University of California, San Francisco, United States     |
| 12h30  | **Award Ceremony**                                                              |                                                                          |
| 12h45  | **Closing Remarks**  
Françoise Barré-Sinoussi, France  
Jack Whitescarver, United States |                                                                          |